timothy sykes logo
Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals Thumbnail
G Google News

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

JACK KELLOGG•UPDATED OCT. 5, 2026, 4:47 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Twist Bioscience Corporation stocks have been trading up by 10.19 percent after upbeat synthetic DNA demand news boosted investor optimism.

Key Takeaways For TWST Traders

  • Shares of Twist Bioscience (TWST) have ripped higher as traders react to a new antibody data deal with Eli Lilly’s AI/ML drug discovery platform, TuneLab.
  • Wall Street is chasing TWST higher, with Leerink lifting its price target twice in September and Guggenheim now modeling upside to $212.
  • UBS started coverage on TWST at Neutral but with a sizeable $144 target, signaling rich expectations despite some caution on valuation.
  • TWST is positioning as a “picks-and-shovels” data supplier to AI drug discovery, guiding toward adjusted EBITDA breakeven by Q4 FY26.

Candlestick Chart

Live Update At 16:46:39 EDT: On Monday, October 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 10.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Twist Bioscience, ticker TWST, is behaving like a classic high-growth, high-expectation name. On the chart, TWST has exploded from about $121 on 2026/09/10 to $205 by 2026/10/05. That is a massive multi-week trend, with only shallow pullbacks along the way. Traders are clearly paying up for the story.

Daily candles show strong momentum: higher lows from mid-September and multiple breakouts over prior resistance levels. Intraday on 2026/10/05, TWST mostly pinned between $200 and $208, holding gains into the close. That kind of tight, elevated consolidation after a run is what momentum traders watch for follow-through.

Fundamentals tell a different, but important, story. TWST generated about $118.4M in quarterly revenue, with a healthy 52% gross margin. But the company is still losing money, posting a net loss of roughly $35.1M and an EBITDA margin of about -23% for the quarter. Cash burn is narrowing: operating cash flow was slightly positive at $1.1M, and free cash flow was about -$8.6M.

More Breaking News

Balance sheet strength helps support this speculative trade. Twist Bioscience holds around $166.8M in cash and short-term investments, a current ratio of 2.7, and low leverage with total debt-to-equity of 0.21. For traders, TWST is a rich, high price-to-sales name powered by growth and AI hype, not traditional earnings metrics.

Why Traders Are Watching TWST Right Now

Twist Bioscience is in the middle of the hottest crossover trade on the market: AI meets biotech. TWST has signed an agreement with Eli Lilly’s AI/ML drug discovery platform, TuneLab, to provide antibody characterization data and related services. In simple terms, Lilly’s AI models need high-quality lab data, and Twist Bioscience is becoming one of the suppliers.

For active traders, that Lilly TuneLab deal is more than headline fluff. It plugs TWST’s wet-lab engine directly into a Big Pharma AI stack. TuneLab users can order antibody services via preferred Twist protocols, feeding data straight into Lilly’s models like AbLab to accelerate antibody discovery. That kind of integration looks like a recurring data pipeline, not a one-off contract, and the market noticed. Multiple reports show TWST shares jumped several percent on the day of the announcement.

Wall Street is now leaning hard into the story. Leerink has raised its Twist Bioscience price target twice, first from $120 to $160, then to $190, all while sticking with an Outperform rating. Their argument: revenue guidance still looks conservative, and pharma adoption of the TWST platform is becoming clearer.

Guggenheim went even more aggressive, more than doubling its target from $107 to $212 and keeping a Buy call as it refreshed models ahead of Q3 earnings. That kind of dramatic target reset tells traders that the sell side was behind the curve on Twist Bioscience’s AI-levered growth path.

At the same time, UBS entered with a Neutral at $144, acknowledging TWST’s upside but signaling valuation and execution questions. Add in confirmation that Twist Bioscience is already working on AI-designed mini-binder proteins for Anthropic—baked into its 2027 outlook—and you get a narrative of TWST as an emerging picks-and-shovels name for both pharma and AI players.

Conclusion

Twist Bioscience has shifted from a niche synthetic biology story to a front-row name in AI-driven drug discovery. TWST is deepening its role as a data supplier to Lilly’s TuneLab while reporting strong revenue growth, expanding margins, and a target of adjusted EBITDA breakeven by Q4 FY26. For traders, that path toward breakeven is a key de-risking milestone for a company that still runs negative profit margins today.

The chart confirms that sentiment. TWST has gone almost straight up over the last few weeks, holding above prior resistance and closing strong near $205 on 2026/10/05. Price-to-sales near 29 and steep negative returns on equity show that Twist Bioscience remains a high-expectation momentum play, not a value name. Insider activity, including a small sale by CEO Emily Leproust while she retains over 600,000 shares, adds a realistic reminder that management is still heavily tied to the stock’s fate.

For the Tim Sykes-style trader, this is the kind of name you study obsessively: big story, big range, and plenty of volatility. As Tim likes to say, “Patterns repeat because human nature doesn’t change—your job is to recognize the pattern and manage your risk.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. With Twist Bioscience, traders have a clear pattern of AI-fueled hype, strong analyst upgrades, and a rising price trend. The edge comes from respecting that momentum while staying disciplined on position size and stop levels. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”